All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Acidified nitrite,Edetate Disodium
Therapeutic Area: Infections and Infectious Diseases Product Name: AB569
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
Paper published in the journal PloS One demonstrated that AB569 kills multi-drug resistant strains of Acinetobacter baumannii and Acinetobacter spp. bacteria.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DPX-COVID-19
Therapeutic Area: Infections and Infectious Diseases Product Name: DPX-COVID-19
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2020
Details:
The Company has successfully completed preclinical safety, GLP toxicology as well as immunogenicity and challenge studies confirming a favorable safety profile and potential for the long duration of antibody titers and protection against SARS-CoV-2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 24, 2020
Details:
To support the patent examination request, the Company has provided the USPTO with new formulation analyses of different diluted concentrations of its Quicksol Ivermectin in solution, data that the company had fast-tracked for completion and validation by a third-party CRO.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVAC-2
Therapeutic Area: Infections and Infectious Diseases Product Name: COVAC-2
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Vaccine Formulation Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
The authorization from Health Canada enables the Canadian Center for Vaccinology (CCfV) in Halifax to begin recruiting volunteers for the first Phase 1 clinical trial of COVAC-2 vaccine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATI-1701
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1701
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Defense Threat Reduction Agency
Deal Size: $6.3 million Upfront Cash: Undisclosed
Deal Type: Funding October 27, 2020
Details:
Agreement with Ology Bioservices and a $6.3MM DTRA contract enable next stage of manufacturing and development for world’s first vaccine to prevent F. tularensis, a potential biological weapons threat.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Apabetalone was shown to inhibit expression of Angiotensin-converting enzyme 2 (ACE2), the receptor utilized by the novel coronavirus to enter human cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LCTG-001
Therapeutic Area: Infections and Infectious Diseases Product Name: LCTG-001
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Icahn School of Medicine
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration October 14, 2020
Details:
Lactiga entered a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients. Partners secured an NIH R01 Emergency Award of over $2MM to advance this study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VBI-2901
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2901
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: VBI Vaccines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 18, 2020
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
